Immunology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

This Phase 2 trial is investigating emapalumab as a treatment for APECED enteritis, a rare autoimmune condition where the immune system attacks the intestines. The study includes people aged 2 to 75 and aims to see if emapalumab can reduce symptoms and improve gut health over 18 months. If successful, this could provide a new option for patients managing this challenging condition.

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

This ongoing Phase 2 trial examines the long-term safety and effectiveness of briquilimab, an antibody treatment for adults with chronic urticaria, a condition causing persistent hives and itching. With 67 participants enrolled across sites in the US and Germany, the study may offer new hope for people whose symptoms have not fully responded to existing treatments.

Vitamin D Supplementation and the Immune Response

This Phase 2 study explores whether vitamin D supplements can improve the immune response to flu vaccination in older adults with vitamin D deficiency. Conducted in France with 37 participants, the trial looks at immune system changes before and after vaccination. Positive results could help enhance infection protection in elderly patients.

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

This Phase 1b/2a trial tested briquilimab in adults with chronic spontaneous urticaria who continue to experience symptoms despite current treatments. With 87 participants from the US and Germany, the study sought to identify safe and effective dosing options. Its findings may lead to improved therapies for people with difficult-to-treat hives.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.